Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

Journal of Urology

Volumn 169, Issue 5, 2003, Pages 1670-1675

  Massengill, Jason C ^b   Sun, Leon ^b   Moul, Judd W ^a   Wu, Hongyu ^b   McLeod, David G ^b   Amling, Christopher ^b   Lance, Raymond ^b   Foley, John ^b   Sexton, Wade ^b   Kusuda, Leo ^b   Chung, Andrew ^b   Soderdahl, Douglas ^b   Donahue, Timothy ^b  

^a Center for Prostate Disease Research   (United States)

^b NONE

Author keywords

Neoplasm staging; Prognosis; Prostatectomy; Prostatic neoplasms; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL;

EID: 0344406150     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000062674.43964.d0     Document Type: Article

References (21)

1. Farkas, A., Schneider, D., Perrotti, M., Cummings, K. B. and Ward, W. S.: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostatespecific antigen screening. Urology, 52: 444, 1998
2. Ellison, L. M., Heaney, J. A. and Birkmeyer, J. D.: Trends in the use of radical prostatectomy for treatment of prostate cancer. Eff Clin Pract, 2: 228, 1999
3. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
4. Lu-Yao, G. L., Potosky, A. L., Albertsen, P. C., Wasson, J. H., Barry, M. J. and Wennberg, J. E.: Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst, 88: 166, 1996
5. Huggins, C., Stevens, R. E. and Hodges, C. V.: Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg, 43: 209, 1941
6. English, H. F., Kloszewski, E. D., Valentine, E. G. and Santen, R. J.: Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res, 46: 839, 1986
7. Sheth, A. R., Garde, S. V., Mehta, M. K. and Shah, M. G.: Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Indian J Exp Biol, 30: 157, 1992
8. Jackson, J. A., Waxman, J. and Spiekerman, A. M.: Prostatic complications of testosterone replacement therapy. Arch Intern Med, 149: 2365, 1989
9. Chodak, G. W., Vogelzang, N. J., Caplan, R. J., Soloway, M. and Smith, J. A.: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA, 265: 618, 1991
10. Ribeiro, M., Ruff, P. and Falkson, G.: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol, 20: 605, 1997
11. Chen, S. S., Chen, K. K., Lin, A. T., Chang, Y. H., Wu, H. H. and Chang, L. S.: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int, 89: 710, 2002
12. Iversen, P., Rasmussen, F. and Christensen, I. J.: Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol, suppl., 157: 41, 1994
13. Monda, J. M., Myers, R. P., Bostwick, D. G. and Oesterling, J. E.: The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology, 46: 62, 1995
14. Hoffman, M. A., DeWolf, W. C. and Morgentaler, A.: Is low serum free testosterone a marker for high grade prostate cancer? J Urol, 163: 824, 2000
15. Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology, 49: 327, 1997
16. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. and Stampfer, M. J.: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst, 88: 1118, 1996
17. Imamoto, T., Suzuki, H., Akakura, K., Komiya, A., Nakamachi, H., Ichikawa, T. et al: Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormona]ly treated stage D2 prostate cancer. Endocr J, 48: 573, 2001
18. Zhang, P. L., Rosen, S., Veeramachaneni, R., Kao, J. DeWolf, W. C. and Bubley, G.: Association between prostate cancer and serum testosterone levels. Prostate, 53: 179, 2002
19. Miller, L. R., Partin, A. W., Chan, D. W., Bruzek, D. J., Dobs, A. S., Epstein, J. I. et al: Influence of radical prostatectomy on serum hormone levels. J Urol, 160: 449, 1998
20. Lokeshwar, B. L., Hurkadli, K. S., Sheth, A. R. and Block, N. L.: Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res, 53: 4855, 1993
21. Ghosh, P. K., Ghosh, D., Ghosh, P. and Chaudhuri, A.: Effects of prostatectomy on testicular androgenesis and serum levels of gonadotropins in mature albino rats. Prostate, 26: 19, 1995